Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) has unveiled the substantial revenue potential of its latest project, a specialized form of cannabis oil known as Live Rosin. This product is celebrated for its purity, potency, and flavor, achieved through a solventless extraction process that preserves the plant's natural properties. The company's proprietary techniques, including Standard Organic Non-Spray Cultivation Procedures (SONSCP), ensure high-quality production with significant output projections.
With the ability to produce an average of 6,000 liters of Live Rosin per 100-acre farm per crop cycle, and up to 5 cycles annually, Pharmagreen is setting the stage for remarkable production volumes. The retail price of Live Rosin ranges from $40 to $100 per gram in the U.S., with even higher prices in Europe, positioning the company for substantial revenue growth. Projections suggest revenues could reach up to $635 million by year 3 at $20 per gram, underscoring the project's lucrative potential.
To capitalize on this opportunity, Pharmagreen is pursuing strategic partnerships and considering the acquisition of a cGMP-certified cannabis lab in Europe. This move aims to facilitate entry into the European market, where Live Rosin commands premium prices. However, the realization of these projections hinges on achieving several critical milestones, including securing necessary licenses, permits, and funding.
CEO Peter Wojcik expressed optimism about the project's future, emphasizing the promising revenue projections and the company's progress towards its goals. Pharmagreen's initiative not only highlights the evolving landscape of the cannabis industry but also showcases the potential for significant economic impact through innovative cultivation and processing technologies.
